Approach to radiation therapy in hepatocellular carcinoma

Cancer Treatment Reviews

Volumn 36, Issue 2, 2010, Pages 157-163

  Ma, Shumei ^a   Jiao, Benzheng ^a   Liu, Xin ^a   Yi, Heqing ^a   Kong, Dejuan ^a   Gao, Lin ^a   Zhao, Guangtong ^a   Yang, Yu ^b   Liu, Xiaodong ^a,c  

^a Center for Radiological Research   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

3D CRT; Hepatocellular carcinoma; Radiation therapy; SRT; TACE

Indexed keywords

IODINATED POPPYSEED OIL; IODINE 131; PHOSPHORUS 32; RHENIUM 188; YTTRIUM 90; HEAVY ION; PROTON;

ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DOSE RESPONSE; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PHOTON THERAPY; PROTON THERAPY; RADIATION DOSE; RADIATION INDUCED HEPATIC TOXICITY; RADIATION INDUCED LIVER DISEASE; RADIATION INJURY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; THREE DIMENSIONAL IMAGING; TRANSARTERIAL RADIOEMBOLIZATION; LIVER TUMOR; METHODOLOGY; PATHOLOGY; STEREOTACTIC PROCEDURE; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; HEAVY IONS; HUMANS; LIVER NEOPLASMS; PROTONS; RADIOTHERAPY, CONFORMAL; STEREOTAXIC TECHNIQUES; TREATMENT OUTCOME;

EID: 77950614243     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.11.008     Document Type: Review

References (83)

1. Lau W.Y., Lai E.C.H. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008, 7:237-257.
2. Hawkins M.A., Dawson L.A. Radiation therapy for hepatocellular carcinoma from palliation to cure. Cancer 2006, 106:1653-1661.
3. Blum H.E., Spangenberg H.C. Hepatocellular carcinoma: an update. Arch Iranian Med 2007, 10:361-371.
4. Yamamoto J., Kosuge T., Saiura A., et al. Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol 2007, 37:287-295.
5. Yamamoto M., Takasaki K., Otsubo T., et al. Favorable surgical outcomes in patients with early hepatocellular carcinoma. Ann Surg 2004, 239(3):395-399.
6. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small epatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699.
7. Lin N.C., Hsia C.Y., Loong C.C., et al. Liver transplantation at a small-volume procedure center-preliminary results from Taipei Veterans general hospital. J Chin Med Assoc 2008, 4:186-190.
8. Schafer D.F., Sorrell M.F. Hepatocellular carcinoma. Lancet 1999, 353:1253-1257.
9. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
10. Kennedy J.E. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 2005, 5(4):321-327.
11. Lau W.Y., Leung T.W., Yu S.C., et al. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003, 237(2):171-179.
12. Huang G.T., Lee P.H., Tsang Y.M., et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005, 242(1):36-42.
13. Chen M.S., Li J.Q., Zheng Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006, 243(3):321-328.
14. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(2):429-442.
15. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171.
16. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials. Radiology 2002, 224:47-54.
17. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002, 359:1734-1739.
18. Doval D.C., Pande S.B., Sharma J.B., et al. Prometheus' spirit: quality survival in advanced hepatocellular carcinoma after gemcitabine and cisplatin-based chemotherapy. Singapore Med J 2008, 49(10):293-295.
19. Hsieh C.H., Jeng K.S., Lin C.C., et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009, 29(1):65-71.
20. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122.
21. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31:1237-1248.
22. Choi B.O., Jang H.S., Kang K.M., et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 2006, 36(3):154-158.
23. Guo W.J., Yu E.X., Liu L.M., et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003, 9:1697-1701.
24. Park H.C., Seong J., Han K.H., et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54(1):150-155.
25. Mornex F., Girard N., Beziat C., Kubas A., Khodri M., Trepo C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66(4):1152-11528.
26. Cheng J.C., Wu J.K., Huang C.M., et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003, 56:229-234.
27. Guo W.J., Yu E.X., Liu L.M., et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003, 9:1697-1701.
28. Yamada K., Izaki K., Sugimoto K., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003, 57:113-119.
29. Wu D.H., Liu L., Chen L.H. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2004, 10:2184-2189.
30. Li B., Yu J., Wang L., et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with Stage III hepatocellular carcinoma. Am J Clin Oncol 2003, 26:e92-e99.
31. Liu M.T., Li S.H., Chu T.C., et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 2004, 34(9):532-539.
32. Liang S.X., Zhu X.D., Lu H.J., et al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005, 103(10):2181-2188.
33. Seo Y.S., Kim J.N., Keum B., et al. Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2008, 14(15):2394-2400.
34. Nakagawa K., Yamashita H., Shiraishi K., et al. Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005, 11(46):7237-7241.
35. Kim D.Y., Park W., Lim D.H., et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005, 103(11):2419-2426.
36. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951, 102:316-319.
37. Lax I., Blomgren H., Naslund I., et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994, 33:677-683.
38. Rades D., Bohlen G., Pluemer A., et al. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer 2007, 109(12):2515-2521.
39. Lin C.S., Jen Y.M., Chiu S.Y., et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006, 36(4):212-217.
40. WJ G.U.O., EX Y.U. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 2000, 73(874):1091-1097.
41. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(2):429-442.
42. Tazawa J., Maeda M., Sakai Y., et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001, 16:660-665.
43. Zeng Z.C., Fan J., Tang Z.Y., et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005, 61:432-443.
44. Ishikura S., Ogino T., Furuse J., et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002, 25:189-193.
45. Yoshikawa M., Ebara M., Ohto M., et al. A combination treatment of transcatheter arterial embolization (TAE) and irradiation for hepatocellular carcinoma (HCC): evaluation for therapeutic effcacy in comparison with TAE or irradiation alone. Jpn J Gastroenterol 1990, 87:225-234.
46. Wu D.H., Liu L., Chen L.H. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2004, 10:2184-2189.
47. Tournoux C., Paoletti X., Barbare J.C. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2007, 33(8):762-763.
48. You C.R., Jang J.W., Kang S.H., et al. Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis. Korean J Hepatol 2007, 13(3):378-386.
49. Zhou Z.H., Liu L.M., Chen W.W., Men Z.Q., et al. Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 2007, 80(951):194-201.
50. Chiba T., Tokuuye K., Matsuzaki Y., et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005, 11:3799-3805.
51. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991, 214(3):221-228.
52. Carr B.I., Selby R., Madariaga J., et al. Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Transplant Proc 1993, 25:1128-1129.
53. Hashimoto T., Tokuuye K., Fukumitsu M., et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 65(1):196-202.
54. Mizumoto M., Tokuuye K., Sugahara S., et al. proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatic. Int J Radiat Oncol Biol Phys 2008, 71(2):462-467.
55. Hata M., Tokuuye K., Sugahara S., et al. Proton irradiation in a single fraction for hepatocellular carcinoma patients with uncontrollable ascites. Technical considerations and results. Strahlenther Onkol 2007, 183(8):411-416.
56. McCormack L., Petrowsky H., Clavien P.A. Surgical therapy of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005, 17:497-503.
57. Kato H., Tsujii H., Miyamoto T., et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004, 59(5):1468-1476.
58. Lau W.Y. Radiotherapy with emphasis on radioembolization for liver tumors. Surgery of the liver and biliary tract 2000, 1545-1564. W.B. Saunders, London. 2nd ed., vol. II. L.H. Blumgart, Y. Fong (Eds.).
59. Ibrahim S.M., Lewandowski R.J., Sato K.T., et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008, 14:1664-1669.
60. Kumar A., Srivastava D.N., Chau T.T.M., et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment-prospective multicenter clinical trial. Radiology 2007, 243:509-519.
61. Liepe K., Brogsitter C., Leonhard J., et al. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn J Clin Oncol 2007, 37(12):942-950.
62. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005, 16:205-213.
63. Kennedy A.S., Coldwell D., Nutting C., et al. Resin Y-90-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006, 65:412-425.
64. Rivera L., Giap H., Miller W., et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol 2006, 12:5729-5732.
65. Novell J.R., Green A.J., Hilson A.J.W., Dick R., Hobbs K.E.F., et al. Selective radionuclide localization in primary liver tumors. HPB Surg 1994, 7:185-200.
66. Nakakuma K., Tashiro S., Ucrnura K., et al. An attempt for increasing effects of hepatic artery ligation for advanced hepatoma (English abstract). Jap-Deutsche Med Beriehte 1979, 24:675-682.
67. Raoul J., Bourguet P., Bretagne J., et al. Hepatic artery injection of 1-131-1abelled lipiodol. Part I: biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988, 168:541-545.
68. Raoul J.L., Duvauferrier R., Bourguet P., et al. Angiography with 131-iodine-labelled iodized oil in malignant hepatoma. J Radiol 1986, 67:797-801.
69. Tsai C., Kusumoto Y., Harada R., et al. Effect of intrahepatic arterial infusion of 131I-labelled lipiodol on hepatocellular carcinoma of rat. Ann Acad Med Singapore 1986, 15:521-524.
70. Ho S., Lau W.Y., Leung T.W., et al. Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Cancer 1998, 83:1894-1907.
71. Jeune J.L., Bourguet P., Victor G., et al. 131-lipiodol in the treatment of hepatocellular carcinoma: results of a multicenter phase II study of fifty patients. Eur J Nucl Med 1990, 16(Suppl.):S143.
72. Leung W.T., Lau W.Y., Ho S., et al. Selective internal radiation therapy with intraarterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994, 35:1313-1318.
73. Luo Y.Q., Wang Y., ChenHet M., et al. Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002, 1:523-526.
74. Yamasaki S., Hasegawa H., Kinoshita H., et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996, 87:206-211.
75. Boucher E., Corbinais S., Rolland Y., et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003, 38:1237-1241.
76. Liu L., Jiang Z., Teng G.J., et al. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma. World J Gastroenterol 1999, 5:492-505.
77. Zheng D.X. Advance in apoptosis research. Chin J Pathol 1996, 25:50-53.
78. Wang Y.Y., Wang D.Z., Zheng G.Y., et al. Apoptosis induced by interstitial irradiation with 32P glass microspheres combination with hyperthermia in mouth solid tumor S180. Huaxi Kouqiang Yixue Zazhi 2001, 19:118-119.
79. Wang X.M., Yin Z.Y., Yu R.X., et al. Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy. World J Gastroenterol 2008, 14:518-523.
80. Kim T.H., Kim D.Y., Park J.W., et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unrespectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(1):225-231.
81. Cheng J.C., Wu J.K., Huang C.M., et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002, 54(1):156-162.
82. Xu Z.Y., Liang S.X., Zhu J., et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 2006, 65(1):189-195.
83. Shirai S., Sato M., Suwa K., et al. Single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus. Int J Radiat Oncol Biol Phys 2009, 73(3):824-831.